PDCD1 and pancreatic neoplasm: Blocking agents targeting the PD-1/PD-L1 pathway also disrupt the PI3K/AKT/mTOR pathway, resulting in inhibition of pancreatic cancer growth, progression and metastatic potential, as observed in an orthotopic mouse model of PDAC.